Abstract
Aim: To determine the safety and efficacy of 0.5mg intramuscular (IM) epinephrine for the treatment of subcutaneous allergen immunotherapy induced anaphylaxis. Patients & methods: Retrospective chart review of patients who received 0.5mg of IMepinephrine for treatment of anaphylaxis from subcutaneous allergen immunotherapy at two outpatient allergy and immunology practices. Results: Thirty-eight patients received 0.5mg IMepinephrine. Eleven patients (29%) required a second dose, and two patients (5%) required a third dose of IMepinephrine. Sixteen patients (42%) were transferred to the emergency department with ongoing symptoms. All had eventual resolution of anaphylaxis. There were no adverse reactions or fatalities. Conclusion: IMepinephrine at a doseof0.5mgis safe and effective for treatment of anaphylaxis from subcutaneous allergen immunotherapy.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call